| Patent Number |
Title Of Patent |
Date Issued |
| 7351792 |
Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor |
April 1, 2008 |
| Nucleic acid molecules encoding the C140 cell surface receptor have been cloned and sequenced. The availability of C140 receptor DNA permits the recombinant production of the C140 receptor which can be produced on the surface of a cell, including an oocyte. The nucleic acid molecules are |
| 7119182 |
Recombinant thrombin receptor and related pharmaceuticals |
October 10, 2006 |
| The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the detection of thrombin and for |
| 6693109 |
Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
February 17, 2004 |
| This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation. |
| 6667306 |
Platelet ADP receptor inhibitors |
December 23, 2003 |
| The invention relates to novel compounds of formula (I) containing fused heterocyclic ring systems which are effective platelet ADP receptor inhibitors: ##STR1##In formula (I), W is carbon or nitrogen, wherein at least one W is a carbon; and Y is nitrogen, oxygen, or sulfur. Such com |
| 6528534 |
Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
March 4, 2003 |
| This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation. |
| 6525076 |
Selective factor Xa inhibitors |
February 25, 2003 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6369080 |
Selective factor Xa inhibitors |
April 9, 2002 |
| Novel compounds of formula I: ##STR1##including its pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositi |
| 6369063 |
Selective factor Xa inhibitors |
April 9, 2002 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6297026 |
Nucleic acids encoding the C140 receptor |
October 2, 2001 |
| Nucleic acid molecules encoding the C140 cell surface receptor have been cloned and sequenced. The availability of C140 receptor DNA permits the recombinant production of the C140 receptor which can be produced on the surface of a cell, including an oocyte. The nucleic acid molecules are |
| 6291469 |
Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
September 18, 2001 |
| This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, as shown by formula (I): ##STR1##wherein Q, L, A.sub.i, B.sub.j, R.sub.0, R.sub.3, R.sub.10, m, n, p and q are as defined in the disclosure, which are useful in inhibiting of |
| 6262047 |
Selective factor Xa inhibitors |
July 17, 2001 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6245743 |
Inhibitors of factor Xa |
June 12, 2001 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6211183 |
Selective factor Xa inhibitors |
April 3, 2001 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6211154 |
Ketoheterocyclic inhibitors of factor Xa |
April 3, 2001 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6204268 |
Selective factor Xa inhibitors |
March 20, 2001 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6197748 |
Ketoheterocyclic inhibitors of factor Xa |
March 6, 2001 |
| Ketoheterocyclic compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are usefull in vitro or in vivo for preventing or treating coagulation disorders. |
| 6194435 |
Lactams as selective factor Xa inhibitors |
February 27, 2001 |
| Novel lactams, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds of Formula I below: ##STR1##are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6133256 |
Selective factor Xa inhibitors |
October 17, 2000 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6069130 |
Ketoheterocyclic inhibitors of factor Xa |
May 30, 2000 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6063794 |
Selective factor Xa inhibitors |
May 16, 2000 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6046169 |
Inhibitors of factor XA |
April 4, 2000 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6043212 |
Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor |
March 28, 2000 |
| Nucleic acid molecules encoding the C140 cell surface receptor have been cloned and sequenced. The availability of C140 receptor DNA permits the recombinant production of the C140 receptor which can be produced on the surface of a cell, including an oocyte. The nucleic acid molecules are |
| 6024936 |
Antibody-based method of localizing activated thrombin receptors |
February 15, 2000 |
| The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the detection of thrombin and for the |
| 6022861 |
Ketoheterocyclic inhibitors of factor Xa |
February 8, 2000 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 5968902 |
Platelet aggregation inhibitors |
October 19, 1999 |
| The isolated and purified PAI from several active snake venoms is described and characterized. In addition, PAIs lacking the Arg-Gly-Asp (RGD) adhesion sequence but containing K* -(G/Sar)-D wherein K* is a modified lysyl residue of the formulawherein each R.sup.1 is independently H, alky |
| 5958732 |
Platelet aggregation inhibitors |
September 28, 1999 |
| An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolate |
| 5935926 |
Platelet aggregation inhibitors |
August 10, 1999 |
| An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolate |
| 5919765 |
Inhibitors of factor XA |
July 6, 1999 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 5916908 |
Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases |
June 29, 1999 |
| A method for selectively inhibiting a kinase is disclosed, which comprises contacting a composition containing a kinase with a compound of the formula: ##STR1## wherein: R.sub.1 is lower alkyl, lower hydrocarbyl, aryl lower alkyl, heteroaryl lower alkyl, 5- or 6-membered heterocy |
| 5874400 |
Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor |
February 23, 1999 |
| Nucleic acid molecules encoding the C140 cell surface receptor have been cloned and sequenced. The availability of C140 receptor DNA permits the recombinant production of the C140 receptor which can be produced on the surface of a cell, including an oocyte. The nucleic acid molecules are |
| 5866681 |
Thrombin receptor antagonists |
February 2, 1999 |
| Peptide derivatives serving as thrombin receptor antagonists are disclosed, which bear specificity for the cellular thrombin receptor without interfering with the catalytic activities of thrombin. The derivatives generally have the formula ##STR1## in which R.sup.1 and R.sup.3 ar |
| 5851839 |
Platelet aggregation inhibitors |
December 22, 1998 |
| Peptides useful in inhibiting platelet aggregation are disclosed. These peptides contain the binding sequence Har-G-D and are disulfide-bridged cyclic compounds. |
| 5843897 |
Platelet aggregation inhibitors |
December 1, 1998 |
| An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolate |
| 5807828 |
Platelet aggregation inhibitors |
September 15, 1998 |
| Peptides useful in inhibiting platelet aggregation are disclosed. These peptides contain the binding sequence Har-G-D and are disulfide-bridged cyclic compounds. |
| 5807825 |
Platelet aggregation inhibitors |
September 15, 1998 |
| An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolate |
| 5798248 |
Recombinant mutant thrombin receptor and related pharmaceuticals |
August 25, 1998 |
| Proteolytically inactive thrombin mutated at positions 43 and/or 99 and/or 205, whereby said mutation renders thrombin an antagonist of thrombin receptor. |
| 5795868 |
Platelet aggregation inhibitors |
August 18, 1998 |
| Peptides useful in inhibiting platelet aggregation are disclosed. These peptides contain the binding sequence Har-G-D and are disulfide-bridged cyclic compounds. |
| 5795867 |
Platelet aggregation inhibitors |
August 18, 1998 |
| Peptides useful in inhibiting platelet aggregation are disclosed. These peptides contain the binding sequence Har-G-D and are disulfide-bridged cyclic compounds. |
| 5786333 |
Platelet aggregation inhibitors |
July 28, 1998 |
| An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolate |
| 5780595 |
Platelet aggregation inhibitors |
July 14, 1998 |
| Peptides useful in inhibiting platelet aggregation are disclosed. These peptides contain the binding sequence Har-G-D and are disulfide-bridged cyclic compounds. |
| 5770564 |
Platelet aggregation inhibitors |
June 23, 1998 |
| An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolate |
| 5763575 |
Agonist and antagonist peptides of the C140 receptor |
June 9, 1998 |
| Nucleic acid molecules encoding the C140 cell surface receptor have been cloned and sequenced. The availability of C140 receptor DNA permits the recombinant production of the C140 receptor which can be produced on the surface of a cell, including an oocyte. The nucleic acid molecules are |
| 5759999 |
Platelet aggregation inhibitors |
June 2, 1998 |
| An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolate |
| 5759994 |
Recombinant thrombin receptor and related pharmaceuticals |
June 2, 1998 |
| The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the detection of thrombin and for the |
| 5756451 |
Platelet aggregation inhibitors |
May 26, 1998 |
| This invention relates to a group of peptides which are, or are related to, platelet aggregation inhibitors isolated and purified from various snake venoms. The instant platelet aggregation inhibitors inhibit (a) binding of Fg or vWF to GPIIb-IIIa more than (b) binding of vitronectin to |
| 5744584 |
Antithrombosis agents |
April 28, 1998 |
| Platelet antiadhesives (PAA) which are useful as antithrombotics are obtainable from snake venoms which have been identified using an assay which measures the ability of the venom to inhibit ristocetin- or botrocetin-induced agglutination of platelets in the presence of von Willebran |
| 5736339 |
Method utilizing purified GP IIb-IIIa to detect the presence of platelet aggregation inhibitors |
April 7, 1998 |
| An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolate |
| 5721214 |
Inhibitors of factor Xa |
February 24, 1998 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 5716789 |
Method to determine ligands, agonist and antagonist of C140 receptor |
February 10, 1998 |
| Nucleic acid molecules encoding the C140 cell surface receptor have been cloned and sequenced. The availability of C140 receptor DNA permits the recombinant production of the C140 receptor which can be produced on the surface of a cell, including an oocyte. The nucleic acid molecules are |
| 5688768 |
Recombinant thrombin receptor and related pharmaceuticals |
November 18, 1997 |
| The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the detection of thrombin and for the |
